Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INTS NASDAQ:OTLK NASDAQ:PDSB NASDAQ:RADX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINTSIntensity Therapeutics$0.28-89.4%$0.00$0.26▼$4.94$13.74M3.173.27 million shs73,559 shsOTLKOncobiologics$1.09-0.5%$1.54$0.79▼$6.98$48.20M0.561.65 million shs1.69 million shsPDSBPDS Biotechnology$0.95-1.0%$1.14$0.85▼$3.75$44.82M1.11542,983 shs269,538 shsRADXRadiopharm Theranostics$7.11+0.3%$5.67$3.50▼$50.82$56.03MN/A87,321 shs8,609 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINTSIntensity Therapeutics+1.79%+15.85%+1.79%-3.72%-92.40%OTLKOncobiologics+2.83%+2.83%+16.58%-42.33%-79.16%PDSBPDS Biotechnology-5.62%-4.68%-19.78%-24.20%-74.05%RADXRadiopharm Theranostics+14.35%+22.24%+23.30%+75.06%+708,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINTSIntensity Therapeutics$0.28-89.4%$0.00$0.26▼$4.94$13.74M3.173.27 million shs73,559 shsOTLKOncobiologics$1.09-0.5%$1.54$0.79▼$6.98$48.20M0.561.65 million shs1.69 million shsPDSBPDS Biotechnology$0.95-1.0%$1.14$0.85▼$3.75$44.82M1.11542,983 shs269,538 shsRADXRadiopharm Theranostics$7.11+0.3%$5.67$3.50▼$50.82$56.03MN/A87,321 shs8,609 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINTSIntensity Therapeutics+1.79%+15.85%+1.79%-3.72%-92.40%OTLKOncobiologics+2.83%+2.83%+16.58%-42.33%-79.16%PDSBPDS Biotechnology-5.62%-4.68%-19.78%-24.20%-74.05%RADXRadiopharm Theranostics+14.35%+22.24%+23.30%+75.06%+708,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINTSIntensity Therapeutics 2.67Moderate Buy$4.501,530.43% UpsideOTLKOncobiologics 2.14Hold$7.00545.16% UpsidePDSBPDS Biotechnology 2.33Hold$10.00949.32% UpsideRADXRadiopharm Theranostics 3.00Buy$15.00110.97% UpsideCurrent Analyst Ratings BreakdownLatest INTS, PDSB, OTLK, and RADX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/30/2025OTLKOncobiologicsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral9/27/2025INTSIntensity TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025OTLKOncobiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025PDSBPDS BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025RADXRadiopharm TheranosticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/22/2025OTLKOncobiologicsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $8.008/29/2025OTLKOncobiologicsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral8/28/2025OTLKOncobiologicsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$3.008/28/2025OTLKOncobiologicsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral8/27/2025OTLKOncobiologicsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/20/2025INTSIntensity TherapeuticsBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSpeculative Buy$4.00 ➝ $1.50(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINTSIntensity TherapeuticsN/AN/AN/AN/A$0.19 per shareN/AOTLKOncobiologics$1.51M32.02N/AN/A($3.09) per share-0.35PDSBPDS BiotechnologyN/AN/AN/AN/A$0.51 per shareN/ARADXRadiopharm Theranostics$2.35M23.84N/AN/A$3.52 per share2.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINTSIntensity Therapeutics-$16.27M-$1.07N/AN/AN/AN/A-612.44%-287.43%N/AOTLKOncobiologics-$75.37M-$0.57N/AN/AN/AN/AN/A-332.30%12/26/2025 (Estimated)PDSBPDS Biotechnology-$37.61M-$0.92N/AN/AN/AN/A-184.56%-79.00%11/13/2025 (Estimated)RADXRadiopharm Theranostics-$24.83MN/A0.00∞N/AN/AN/AN/AN/ALatest INTS, PDSB, OTLK, and RADX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q3 2025OTLKOncobiologics-$0.42-$0.44-$0.02-$0.55$1.66 million$1.51 million8/13/2025Q2 2025PDSBPDS Biotechnology-$0.24-$0.21+$0.03-$0.21N/AN/A8/7/2025Q2 2025INTSIntensity TherapeuticsN/A-$0.13N/A-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINTSIntensity TherapeuticsN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ARADXRadiopharm TheranosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINTSIntensity Therapeutics0.041.401.40OTLKOncobiologicsN/A0.670.54PDSBPDS Biotechnology0.812.922.92RADXRadiopharm TheranosticsN/A2.672.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINTSIntensity Therapeutics3.74%OTLKOncobiologics11.20%PDSBPDS Biotechnology26.84%RADXRadiopharm TheranosticsN/AInsider OwnershipCompanyInsider OwnershipINTSIntensity Therapeutics7.10%OTLKOncobiologics4.80%PDSBPDS Biotechnology9.20%RADXRadiopharm TheranosticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINTSIntensity Therapeutics2,02149.06 million45.57 millionNot OptionableOTLKOncobiologics2044.42 million42.29 millionOptionablePDSBPDS Biotechnology2047.03 million42.70 millionOptionableRADXRadiopharm TheranosticsN/A7.88 millionN/AN/AINTS, PDSB, OTLK, and RADX HeadlinesRecent News About These CompaniesRadiopharm receives DSMC recommendation to advance Phase 1 ‘HEAT’ trialOctober 1, 2025 | msn.comRADX: RAD101: Imaging Recurring Brain MetastasesSeptember 29, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025Top 3 Dividend Achievers for October: High Yields, Growth AheadBy Thomas Hughes | October 1, 2025Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallBy Leo Miller | September 15, 2025Micron’s Stock Price Rally Is Not Over: MU $190 Is Coming SoonBy Thomas Hughes | September 25, 2025Beam Global Gets Buy Rating With 101% Upside PotentialBy Nathan Reiff | September 27, 2025INTS, PDSB, OTLK, and RADX Company DescriptionsIntensity Therapeutics NASDAQ:INTSIntensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.Oncobiologics NASDAQ:OTLK$1.08 -0.01 (-0.46%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.PDS Biotechnology NASDAQ:PDSB$0.95 -0.01 (-1.01%) As of 12:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.Radiopharm Theranostics NASDAQ:RADX$7.11 +0.02 (+0.28%) As of 11:55 AM EasternRadiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal 2 Defense Stocks Riding 2025’s Massive Momentum Wave Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? Best Stocks Under $15? 3 Low-Priced Picks With Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
